IC
ACAD icon

InterOcean Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

InterOcean Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$242K Hold
5,000
– – 0.02% 168
2020
Q1 		$211K Hold
5,000
– – 0.02% 167
2019
Q4 		$214K Buy
+5,000
New +$218K 0.02% 188

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

InterOcean Capital's ACAD Position: Q2 2020 in Review

InterOcean Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2020 at 5,000 shares worth $242K. The position accounts for 0.02% of the portfolio, ranked #168.

InterOcean Capital first reported a position in ACAD in Q4 2019 and has held it in 3 quarters since. 297 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • InterOcean Capital held 5,000 shares of Acadia Pharmaceuticals worth $242K as of Q2 2020.
  • InterOcean Capital left its Acadia Pharmaceuticals share count unchanged in Q2 2020.
  • Acadia Pharmaceuticals made up 0.02% of InterOcean Capital's portfolio in Q2 2020, its #168 holding.
  • InterOcean Capital first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • 297 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on InterOcean Capital's 13F filing for Q2 2020, filed 13 Aug 2020.